LIFESTYLE and health factors that are linked with heart disease appear to have a greater impact on cardiovascular risk in women than men, according to a study being presented at the American College of Cardiology’s Annual Scientific Session.
While diet, exercise, smoking, and blood pressure have long been associated with heart disease risk, the new study is the first to indicate that these correlations are higher in women than in males.
LIFESTYLE and health factors that are linked with heart disease appear to have a greater impact on cardiovascular risk in women than men, according to a study being presented at the American College of Cardiology’s Annual Scientific Session.
While diet, exercise, smoking, and blood pressure have long been associated with heart disease risk, the new study is the first to indicate that these correlations are higher in women than in males.
According to the researchers, the findings indicate that sex-specific screening or risk assessment methodologies could provide a more realistic picture of cardiovascular risk and better drive people to adopt heart-healthy habits.
“For the same level of health, our study shows that the increase in risk [related to each factor] is higher in women than in men–it’s not one-size-fits-all,” said Maneesh Sud, MD, PhD, assistant professor in the department of medicine, interventional cardiologist and clinician scientist at Sunnybrook Health Sciences Centre in Toronto and the study’s lead author. “This is novel and something that hasn’t been seen in other studies.”
The study focused on eight factors associated with heart disease: diet, sleep, physical activity, smoking, body mass index, blood glucose, lipids and blood pressure.
Overall, the results showed that women were more likely to have fewer negative risk factors and more positive ones compared with men. However, women with more negative risk factors faced a more pronounced increase in their chance of a heart attack, stroke or other cardiovascular event compared to men with a similar risk factor profile.
“We found that women tend to have better health than men, but the impact on outcomes is different,” Sud said. “The combination of these factors has a bigger impact in women than it does in men.”
The researchers analyzed data from over 175,000 Canadian adults who enrolled in the Ontario Health Study between 2009-2017. None of the participants had heart disease at baseline and about 60 per cent were women. Each participant was classified as having ideal or poor health in terms of each of the eight risk factors, and these scores were combined to calculate an overall risk factor profile as poor (fewer than five positive factors or more than three negative factors), intermediate (five to seven positive factors) or ideal (ideal across all eight factors). During a median follow-up period of just over 11 years, researchers tracked the incidence of seven heart disease outcomes–heart attack, stroke, unstable angina (chest pain that results from restricted blood flow to the heart), peripheral arterial disease (narrowed blood vessels in the arms or legs), heart failure, coronary revascularization (procedures to open blocked arteries) and cardiovascular death–among participants in each of the three groupings.- ANI
Source: The Global New Light of Myanmar
LIFESTYLE and health factors that are linked with heart disease appear to have a greater impact on cardiovascular risk in women than men, according to a study being presented at the American College of Cardiology’s Annual Scientific Session.
While diet, exercise, smoking, and blood pressure have long been associated with heart disease risk, the new study is the first to indicate that these correlations are higher in women than in males.
According to the researchers, the findings indicate that sex-specific screening or risk assessment methodologies could provide a more realistic picture of cardiovascular risk and better drive people to adopt heart-healthy habits.
“For the same level of health, our study shows that the increase in risk [related to each factor] is higher in women than in men–it’s not one-size-fits-all,” said Maneesh Sud, MD, PhD, assistant professor in the department of medicine, interventional cardiologist and clinician scientist at Sunnybrook Health Sciences Centre in Toronto and the study’s lead author. “This is novel and something that hasn’t been seen in other studies.”
The study focused on eight factors associated with heart disease: diet, sleep, physical activity, smoking, body mass index, blood glucose, lipids and blood pressure.
Overall, the results showed that women were more likely to have fewer negative risk factors and more positive ones compared with men. However, women with more negative risk factors faced a more pronounced increase in their chance of a heart attack, stroke or other cardiovascular event compared to men with a similar risk factor profile.
“We found that women tend to have better health than men, but the impact on outcomes is different,” Sud said. “The combination of these factors has a bigger impact in women than it does in men.”
The researchers analyzed data from over 175,000 Canadian adults who enrolled in the Ontario Health Study between 2009-2017. None of the participants had heart disease at baseline and about 60 per cent were women. Each participant was classified as having ideal or poor health in terms of each of the eight risk factors, and these scores were combined to calculate an overall risk factor profile as poor (fewer than five positive factors or more than three negative factors), intermediate (five to seven positive factors) or ideal (ideal across all eight factors). During a median follow-up period of just over 11 years, researchers tracked the incidence of seven heart disease outcomes–heart attack, stroke, unstable angina (chest pain that results from restricted blood flow to the heart), peripheral arterial disease (narrowed blood vessels in the arms or legs), heart failure, coronary revascularization (procedures to open blocked arteries) and cardiovascular death–among participants in each of the three groupings.- ANI
Source: The Global New Light of Myanmar
NEARLY 60 per cent of all adults and a third of all children in the world will be overweight or obese by 2050 unless governments take action, a large new study said Tuesday.
The research published in the Lancet medical journal used data from 204 countries to paint a grim picture of what it described as one of the great health challenges of the century.
NEARLY 60 per cent of all adults and a third of all children in the world will be overweight or obese by 2050 unless governments take action, a large new study said Tuesday.
The research published in the Lancet medical journal used data from 204 countries to paint a grim picture of what it described as one of the great health challenges of the century.
“The unprecedented global epidemic of overweight and obesity is a profound tragedy and a monumental societal failure,” lead author Emmanuela Gakidou, from the US-based Institute for Health Metrics and Evaluation (IHME), said in a statement.
The number of overweight or obese people worldwide rose from 929 million in 1990 to 2.6 billion in 2021, the study found.
Without a serious change, the researchers estimate that 3.8 billion adults will be overweight or obese in 15 years — — or around
60 per cent of the global adult population in 2050.
The world’s health systems will come under crippling pressure, the researchers warned, with around a quarter of the world’s obese expected to be aged over 65 by that time.
They also predicted a 121-percent increase in obesity among children and adolescents around the world. A third of all obese young people will be living in two regions -- North Africa and the Middle East, and Latin America and the Caribbean -- by 2050, the researchers warned.
But it is not too late to act, said study co-author Jessica Kerr from Murdoch Children’s Research Institute in Australia. “Much stronger political commitment is needed to transform diets within sustainable global food systems,” she said.
That commitment was also needed for strategies “that improve people’s nutrition, physical activity and living environments, whether it’s too much processed food or not enough parks,” Kerr said.
Source: The Global New Light of Myanmar
NEARLY 60 per cent of all adults and a third of all children in the world will be overweight or obese by 2050 unless governments take action, a large new study said Tuesday.
The research published in the Lancet medical journal used data from 204 countries to paint a grim picture of what it described as one of the great health challenges of the century.
“The unprecedented global epidemic of overweight and obesity is a profound tragedy and a monumental societal failure,” lead author Emmanuela Gakidou, from the US-based Institute for Health Metrics and Evaluation (IHME), said in a statement.
The number of overweight or obese people worldwide rose from 929 million in 1990 to 2.6 billion in 2021, the study found.
Without a serious change, the researchers estimate that 3.8 billion adults will be overweight or obese in 15 years — — or around
60 per cent of the global adult population in 2050.
The world’s health systems will come under crippling pressure, the researchers warned, with around a quarter of the world’s obese expected to be aged over 65 by that time.
They also predicted a 121-percent increase in obesity among children and adolescents around the world. A third of all obese young people will be living in two regions -- North Africa and the Middle East, and Latin America and the Caribbean -- by 2050, the researchers warned.
But it is not too late to act, said study co-author Jessica Kerr from Murdoch Children’s Research Institute in Australia. “Much stronger political commitment is needed to transform diets within sustainable global food systems,” she said.
That commitment was also needed for strategies “that improve people’s nutrition, physical activity and living environments, whether it’s too much processed food or not enough parks,” Kerr said.
Source: The Global New Light of Myanmar
SCIENTISTS have found specialized neurons in the brains of mice that order the animals to stop eating. Though many feeding circuits in the brain are known to play a role in monitoring food intake, scientists also believe that the neurons in those circuits do not make the final decision to cease eating a meal.
The neurons identified by the Columbia scientists, a new element of these circuits, are located in the brainstem, the oldest part of the vertebrate brain. Their discovery could lead to new treatments for obesity.
SCIENTISTS have found specialized neurons in the brains of mice that order the animals to stop eating. Though many feeding circuits in the brain are known to play a role in monitoring food intake, scientists also believe that the neurons in those circuits do not make the final decision to cease eating a meal.
The neurons identified by the Columbia scientists, a new element of these circuits, are located in the brainstem, the oldest part of the vertebrate brain. Their discovery could lead to new treatments for obesity.
“These neurons are unlike any other neuron involved in regulating satiation,” says Alexander Nectow, a physician-scientist at Columbia University Vagelos College of Physicians and Surgeons, who led the research with Srikanta Chowdhury, an associate research scientist in the Nectow lab.
“Other neurons in the brain are usually restricted to sensing food put into our mouth, or how food fills the gut, or the nutrition obtained from food. The neurons we found are special in that they seem to integrate all these different pieces of information and more.” The decision to stop eating is a familiar phenomenon. “It happens every time we sit down to eat a meal: At a certain point while we’re eating, we start to feel full, and then we get fuller, and then we get to a point where we think, okay, that’s enough,” Nectow says.
How does the brain know when the body has had enough — and how does it act on that information to stop eating? Other re-
searchers had previously tracked the decision-making cells to the brainstem, but the leads ended there in previous research.
Nectow and Chowdhury deployed new single-cell techniques that make it possible to peer into a region of the brain and discern different types of cells that until now have been difficult to distinguish from one another. “This technique — spatially resolved molecular profiling — allows you to see cells where they are in the brainstem and what their molecular composition looks like,” Nectow says.
During their profiling of a brainstem region known for processing complex signals, the researchers spotted previously unrecognized cells that had similar characteristics to other neurons involved in regulating appetite.
“We said, ‘Oh, this is interesting. What do these neurons do?’ To see how the neurons influenced eating, the researchers engineered the neurons so they could be turned on and off, by the researcher, with light.
When the neurons were activated by the light, the mice ate much smaller meals. The intensity of the activation determined how quickly animals stopped eating.
“Interestingly, these neurons don’t just signal an immediate stop; they help the mice to slow down their eating gradually,” Chowdhury says.
Nectow and Chowdhury also looked at how other eating circuits and hormones affected the neurons. The researchers found that
the neurons were silenced by a hormone that increases appetite and activated by a GLP-1 agonist, a class of drugs now popular for treating obesity and diabetes.
Source : The Global New Light of Myanmar
SCIENTISTS have found specialized neurons in the brains of mice that order the animals to stop eating. Though many feeding circuits in the brain are known to play a role in monitoring food intake, scientists also believe that the neurons in those circuits do not make the final decision to cease eating a meal.
The neurons identified by the Columbia scientists, a new element of these circuits, are located in the brainstem, the oldest part of the vertebrate brain. Their discovery could lead to new treatments for obesity.
“These neurons are unlike any other neuron involved in regulating satiation,” says Alexander Nectow, a physician-scientist at Columbia University Vagelos College of Physicians and Surgeons, who led the research with Srikanta Chowdhury, an associate research scientist in the Nectow lab.
“Other neurons in the brain are usually restricted to sensing food put into our mouth, or how food fills the gut, or the nutrition obtained from food. The neurons we found are special in that they seem to integrate all these different pieces of information and more.” The decision to stop eating is a familiar phenomenon. “It happens every time we sit down to eat a meal: At a certain point while we’re eating, we start to feel full, and then we get fuller, and then we get to a point where we think, okay, that’s enough,” Nectow says.
How does the brain know when the body has had enough — and how does it act on that information to stop eating? Other re-
searchers had previously tracked the decision-making cells to the brainstem, but the leads ended there in previous research.
Nectow and Chowdhury deployed new single-cell techniques that make it possible to peer into a region of the brain and discern different types of cells that until now have been difficult to distinguish from one another. “This technique — spatially resolved molecular profiling — allows you to see cells where they are in the brainstem and what their molecular composition looks like,” Nectow says.
During their profiling of a brainstem region known for processing complex signals, the researchers spotted previously unrecognized cells that had similar characteristics to other neurons involved in regulating appetite.
“We said, ‘Oh, this is interesting. What do these neurons do?’ To see how the neurons influenced eating, the researchers engineered the neurons so they could be turned on and off, by the researcher, with light.
When the neurons were activated by the light, the mice ate much smaller meals. The intensity of the activation determined how quickly animals stopped eating.
“Interestingly, these neurons don’t just signal an immediate stop; they help the mice to slow down their eating gradually,” Chowdhury says.
Nectow and Chowdhury also looked at how other eating circuits and hormones affected the neurons. The researchers found that
the neurons were silenced by a hormone that increases appetite and activated by a GLP-1 agonist, a class of drugs now popular for treating obesity and diabetes.
Source : The Global New Light of Myanmar
Researchers at the University of Colorado developed LL-341070, a therapeutic candidate that accelerates myelin repair in the brain, improving vision and cognitive function. The drug could benefit those with multiple sclerosis and neurodegenerative diseases by enhancing the brain’s natural repair mechanisms and potentially reversing damage, offering hope for recovery.
Researchers at the University of Colorado developed LL-341070, a therapeutic candidate that accelerates myelin repair in the brain, improving vision and cognitive function. The drug could benefit those with multiple sclerosis and neurodegenerative diseases by enhancing the brain’s natural repair mechanisms and potentially reversing damage, offering hope for recovery.
RESEARCHERS at the University of Colorado Anschutz Medical Campus found a promising therapeutic candidate that could aid in the restoration of vision in those suffering from multiple sclerosis (MS) and other neurodegenerative diseases.
The medicine, LL-341070, improves the brain’s ability to repair damaged myelin–the protective sheath that surrounds nerve fibers. Myelin damage is a hallmark of disorders such as MS, as well as a normal consequence of aeing, and it frequently causes visual loss, loss of motor abilities, and cognitive decline.
The research, focused on vision, demonstrated that while the brain has some ability to repair itself when myelin is damaged, the process can be slow and inefficient. Researchers observed that LL-341070 significantly accelerated the repair process and improved brain function related to vision in mice, even after severe damage.
“This research brings us closer to a world where the brain has the capacity to heal itself ” said Ethan Hughes, PhD, co-lead author and associate professor in the Department of Cell and Developmental Biology at the CU School of Medicine.
“By harnessing this potential, we hope to help people with diseases like MS by potentially reversing some of the damage, offering people the opportunity to regain their vision and cognitive function.”
Researchers discovered that the treatment makes the repair process much more effective following serious damage, highlighting the importance of intervention with severe injury. Even partial repair of myelin was found to significantly improve vision-related brain functions.
“We’ve known for years that myelin plays a crucial role in brain function,” said Daniel Denman, PhD, co-lead author of the study and assistant professor in the Department of Physiology and Biophysics at the CU School of Medicine. “This study highlights the role of cortical myelin in visual function. The drug could be a game-changer because it accelerates the brain’s natural repair mechanisms.”
The researchers plan to test the drug in other areas of the brain and refine the treatment, hoping to make it even more effective and eventually accessible to patients. “This discovery is just the beginning,” Hughes said. “We are optimistic that LL-341070 and similar therapies could one day provide real, tangible benefits to patients by improving overall brain function and quality of life.”
Source: The Global New Light of Myanmar
Researchers at the University of Colorado developed LL-341070, a therapeutic candidate that accelerates myelin repair in the brain, improving vision and cognitive function. The drug could benefit those with multiple sclerosis and neurodegenerative diseases by enhancing the brain’s natural repair mechanisms and potentially reversing damage, offering hope for recovery.
RESEARCHERS at the University of Colorado Anschutz Medical Campus found a promising therapeutic candidate that could aid in the restoration of vision in those suffering from multiple sclerosis (MS) and other neurodegenerative diseases.
The medicine, LL-341070, improves the brain’s ability to repair damaged myelin–the protective sheath that surrounds nerve fibers. Myelin damage is a hallmark of disorders such as MS, as well as a normal consequence of aeing, and it frequently causes visual loss, loss of motor abilities, and cognitive decline.
The research, focused on vision, demonstrated that while the brain has some ability to repair itself when myelin is damaged, the process can be slow and inefficient. Researchers observed that LL-341070 significantly accelerated the repair process and improved brain function related to vision in mice, even after severe damage.
“This research brings us closer to a world where the brain has the capacity to heal itself ” said Ethan Hughes, PhD, co-lead author and associate professor in the Department of Cell and Developmental Biology at the CU School of Medicine.
“By harnessing this potential, we hope to help people with diseases like MS by potentially reversing some of the damage, offering people the opportunity to regain their vision and cognitive function.”
Researchers discovered that the treatment makes the repair process much more effective following serious damage, highlighting the importance of intervention with severe injury. Even partial repair of myelin was found to significantly improve vision-related brain functions.
“We’ve known for years that myelin plays a crucial role in brain function,” said Daniel Denman, PhD, co-lead author of the study and assistant professor in the Department of Physiology and Biophysics at the CU School of Medicine. “This study highlights the role of cortical myelin in visual function. The drug could be a game-changer because it accelerates the brain’s natural repair mechanisms.”
The researchers plan to test the drug in other areas of the brain and refine the treatment, hoping to make it even more effective and eventually accessible to patients. “This discovery is just the beginning,” Hughes said. “We are optimistic that LL-341070 and similar therapies could one day provide real, tangible benefits to patients by improving overall brain function and quality of life.”
Source: The Global New Light of Myanmar